Alamar Biosciences Q3 2026 earnings

ALMR · 2026-11-03 16:10 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue grew 68% to $33.5 million, gross margin expanded 1.8 pp to 61.5%, and the company raised full-year revenue guidance to $121-123 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$33.5 million+68%+14%Ex. 99.1, income statement
EPS (GAAP)-$0.19+72.5%+11.8%Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Product revenue$26.3 million+68.2%78.4%Instrument revenue $8.5 million (+50% YoY)
Service and other revenue$7.2 million+68.1%21.6%Custom assay development services

Margins and costs

  • Gross margin 61.5% (prior 59.7%, change +1.8 pp)
  • Operating expenses $35.8 million (+81% YoY)
  • One-offs in the quarter Stock-based compensation: $3.9 million; Interest income: $2.2 million; Interest expense: $0.2 million; Loss on remeasurement of convertible notes: $0.0 million
  • Effective tax rate 0.7% (prior-year 5.8%, year-to-date 1.0%)
  • Non-GAAP bridge Stock-based compensation, cost of revenue adjustments, and interest income/expense are added back to GAAP results to arrive at adjusted metrics.

KPIs

MetricActualPrior quarterPrior yearChange
Cash & equivalents$121.5 million$132.9 million$30.0 million-8.5%
Total cash & investments$231.5 million$256.3 million$30.0 million-9.7%
Weighted-average shares69.1 million58.7 million11.6 million+17.8%

Guidance

MetricGuidePrior guideChange
Full-year 2026 Revenue$121-123 million$116-120 million+$5 million midpoint

What drove it

  • Revenue story Product revenue grew 68% to $26.3 million, led by a 50% increase in instrument revenue to $8.5 million and a 79% increase in consumable revenue to $17.8 million. Services and other revenue grew 69% to $7.2 million.
  • EPS story Net loss narrowed to $13.3 million ($0.19 per share) from $8.0 million ($0.69 per share) in the prior year, driven by higher revenue and a lower tax rate.
  • One-off check Stock-based compensation increased to $3.9 million from $0.7 million in the prior year.

The good

  • Revenue grew 68% YoY to $33.5 million
  • Gross margin expanded 1.8 pp YoY to 61.5%
  • Raised full-year revenue guidance to $121-123 million

The bad

  • Operating expenses increased 81% YoY to $35.8 million
  • Operating loss widened to $15.1 million from $7.9 million

The ugly

  • none

Open questions

  • The release does not disclose the specific mix of biopharma vs. academic revenue or the percentage of revenue from biopharma customers.
  • The release does not provide a reconciliation of GAAP net loss to adjusted net loss.
Full release

Alamar Biosciences (ALMR) earnings release, November 3, 2026

Alamar Biosciences, Inc. (ALMR) · Form 8-K, Item 2.02 · Filed · SEC filing

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended September 30, 2026.

Recent Highlights

• Generated $33.5 million of total revenue for the third quarter of 2026, an increase of 68% as compared to the corresponding period of 2025

• Selected by UK Biobank to profile 80,000 samples for study targeting earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions

• Launched a strategic scientific collaboration with GSK for large-scale 60,000-sample study to advance precision medicine across respiratory, liver, kidney, neurological and autoimmune conditions

• Announced publication of first longitudinal treatment response for Alzheimer’s disease using NULISA platform published in

Lancet Neurology

• Raising full-year 2026 revenue guidance to $121 million to $123 million, representing growth of 64% at the midpoint of the range as compared to 2025

“Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time,” said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. “Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.”

Third Quarter 2026 Financial Results

Revenue was $33.5 million for the third quarter of 2026, a 68% increase from $19.9 million for the corresponding prior-year period. Instrument revenue grew 50% to $8.5 million, from $5.7 million for the corresponding prior-year period, driven primarily by continued growth in new instrument placements. Consumable revenue grew 79% to $17.8 million, from $10.0 million for the corresponding prior-year period, driven primarily by strong demand for multiplex panels. Services and other revenue grew 69% to $7.2 million, from $4.3 million for the corresponding prior-year period, driven primarily by strong demand for custom assay development services.

Gross margin was 61.5% for the third quarter of 2026, as compared to 59.7% for the corresponding prior-year period. The increase in gross margin was primarily driven by lower instrument costs, higher average selling prices for consumables, improved margins on services, and a favorable shift in product mix.

Operating expenses were $35.8 million for the third quarter of 2026, an 81% increase from $19.8 million for the corresponding prior-year period. The year-over-year increase in operating expenses was primarily related to planned investments in headcount, infrastructure and R&D supplies as well as incremental public company costs.

Operating loss was $15.1 million for the third quarter of 2026, as compared to an operating loss of $7.9 million for the corresponding prior-year period. This includes $3.9 million of stock-based compensation for the third quarter of 2026, as compared to $0.7 million for the third quarter of 2025.

Net loss was $13.3 million for the third quarter of 2026 compared to an $8.0 million net loss in the corresponding prior-year period.

Cash, cash equivalents, short-term investments and restricted cash were $231.5 million as of September 30, 2026.

2026 Guidance

Alamar Biosciences now expects full year 2026 revenue to be in the range of $121 to $123 million, representing growth of 64% at the midpoint of the range compared to full year 2025. This compares to its previous expectations of $116 to $120 million for full year 2026.

President Tod White to Retire at Year-End

Tod White, president, will retire from Alamar at the end of 2026, after which he will continue to serve as an advisor to the company through June 2027. Mr. White joined Alamar as chief financial officer and chief business officer in March of 2021 and was promoted to president in October 2025. During his tenure, he led Alamar’s financial organization, scaled its operations, established numerous collaborations and partnerships, and helped guide the company through its initial public offering.

“Tod has been an outstanding partner and leader during a pivotal period for Alamar,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase. On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement.”

“It has been a privilege to work alongside this exceptional team,” said Mr. White. “Their talent, dedication, and belief in what precision proteomics can do to improve human health have driven everything we have accomplished. Alamar is well positioned to lead the next era of proteomics, and I have never been more confident in the company’s future.”

Webcast Information

Alamar Biosciences will host a conference call to discuss the third quarter 2026 financial results after market close on Tuesday, November 3, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investors.alamarbio.com/.

About Alamar Biosciences, Inc.... (truncated)itical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited, in thousands, except share and per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue:
Product revenue26,30015,62870,91036,837
Service and other revenue7,2454,28518,09712,329
Total revenue(1)33,54519,91389,00749,166
Cost of revenue:
Cost of product revenue(2)10,8796,49530,54718,355
Cost of service and other revenue(2)2,0221,5215,6413,944
Total cost of revenue12,9018,01636,18822,299
Gross profit20,64411,89752,81926,867
Operating expenses:
Research and development(2)16,16710,20643,00127,403
Selling, general and administrative(2)19,6169,57650,83623,821
Total operating expenses35,78319,78293,83751,224
Loss from operations-15,139-7,885-41,018-24,357
Interest income, net2,1694104,5831,826
Interest expense-153-85-600-179
Loss on remeasurement of convertible notes-9,971
Other (expense) income, net-125-1-395467
Net loss before income tax-13,248-7,561-47,401-22,243
Provision for income taxes94440465440
Net loss-13,342-8,001-47,866-22,683
Net loss per share, basic and diluted-0.19-0.69-1.02-1.99
Weighted-average common shares outstanding, basic and diluted69,106,36711,599,35346,884,56411,423,840

Income Statement

Three Months Ended September 30, — Includes stock-based compensation expense as follows: (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cost of product revenue64712322
Cost of service and other revenue661414639
Research and development9912402,221731
Selling, general and administrative2,7954446,1731,212
Total stock-based compensation expense3,9167058,6632,004

Balance Sheet

September 30, 2026 — (Unaudited, in thousands)

September 30, 2026December 31, 2025
Current Assets
Cash and cash equivalents121,53230,002
Short-term investments105,053
Accounts receivable21,61112,753
Inventory54,13338,482
Prepaid expenses and other current assets15,35913,468
Total current assets317,68894,705
Restricted cash4,9074,907
Property and equipment, net15,24410,498
Operating lease right-of-use assets36,23626,130
Capitalized software, net1,4431,988
Other assets—noncurrent2,5091,764
Total assets378,027139,992
Current Liabilities
Accounts payable16,5495,872
Accrued and other current liabilities14,45015,759
Short-term operating lease liabilities2,4832,099
Total current liabilities33,48223,730
Long-term operating lease liabilities39,86729,564
Warrant liabilities247
Term debt9,810
Other noncurrent liabilities974599
Total liabilities74,32363,950
Convertible preferred stock234,996
Stockholders’ equity (deficit)
Common stock71
Additional paid-in capital520,5119,892
Accumulated other comprehensive loss-173-72
Accumulated deficit-216,641-168,775
Total stockholders’ equity (deficit)303,704-158,954
Total liabilities, convertible preferred stock and stockholders' equity (deficit)378,027139,992

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (Unaudited, in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-47,866-22,683
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense3,7252,790
Stock-based compensation8,6632,004
Accretion and amortization of premiums and discounts on investments, net-561-145
Loss on remeasurement of convertible notes9,971
Convertible note issuance costs included in net loss361
Unrealized foreign exchange loss (gain)303-167
Non-cash operating lease costs1,7811,451
Amortization of debt issuance costs203125
Change in fair value of warrant liabilities11731
Provision for expected credit losses118
Changes in assets and liabilities:
Accounts receivable-9,143-3,805
Inventory-17,196-18,854
Contract assets69
Net investment in sales-type lease261
Prepaid expenses and other current assets-2,646-3,583
Other noncurrent assets-447-28
Accounts payable9,2901,989

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ future plans and prospects, its ability to accelerate adoption of its platform and establish a new gold standard in protein detection and analysis, anticipated timing and content regarding full-year 2026 guidance, and Alamar Biosciences’ ability to grow its business. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property and other risks and uncertainties described in Alamar Biosciences’ filings with the Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its Quarterly Report on Form 10-Q filed with the SEC, on August 11, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Investor contact: investors@alamarbio.com

Media contact: media@alamarbio.com

Alamar Biosciences, Inc.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share data)

(1)

The following table represents revenue by source for the periods indicated:

(2)

Includes stock-based compensation expense as follows:

Alamar Biosciences, Inc.

Condensed Consolidated Balance Sheets

(Unaudited, in thousands)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Alamar Biosciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.